Volume dodolan perusahaan Merus (MRUS)

Merus NV - logo grafis emiten MRUS

The lack of revenue at biotech startup Merus N.V. (MRUS) drives the stagnation of the company's total sales, where 0.06 indicates the level of this metric. Brand stability is based on its authority in developing cancer antibodies. Intellectual property protection is ensured by patents and strict FDA oversight. High R&D costs create a significant barrier to entry for new players in this niche.

Pendapatan lan volume dodolan: Merus (MRUS) kanggo 04.07.2022 - 10.01.2026

Rincian analitis perusahaan Merus (MRUS)

- rega pasar lan target rega analis:
Rega bursa Merus Therapeutics|MRUS - Bagan rega target
- rincian kapitalisasi pasar:
Kapitalisasi pasar Merus N.V.|MRUS - Nilai Total Perusahaan
- statistik nilai buku emiten:
Nilai Akuntansi saben Saham Merus|MRUS - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku merus.nl|MRUS - Aset Agregat Perusahaan
- data liabilitas lan likuiditas perusahaan:
Rasio Kabeh Utang marang Dana Pribadi Merus N.V.|MRUS - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Merus NV|MRUS - Utang perusahaan|Utang-utang marang aset resik Merus N.V.|MRUS - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Merus|Rasio likuiditas darurat merus.nl
- indikator profitabilitas perusahaan lan kelipatan valuasi:
MRUS - Penghasilan resik|Prakiraan bathi perusahaan Merus N.V.|MRUS - Koefisien rega marang bathi|Rega marang bathi mangsa ngarep merus.nl|MRUS - Pangali rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Merus N.V.|MRUS - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Merus|MRUS - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan merus.nl|MRUS - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Merus N.V.
- statistik dodolan lan pendapatan perusahaan:
MRUS - Pendapatan perusahaan|Dodolan mangsa ngarep perusahaan Merus Therapeutics|MRUS - Multiplikator P/S|Multiplikator forward rega marang pendapatan Merus N.V.
Analisis komprehensif perusahaan:Merus N.V.
Barang unggulan Merus

This metric measures the aggregate cash flow from product sales, allowing for an assessment of operational efficiency and business scaling rates through revenue analysis. By examining the sales volume dynamics of Merus N.V. (MRUS), an investor can correlate the financial growth of Merus N.V. (MRUS) with the development success of petuzumab and the potential execution of strategic agreements with major oncology market behemoths.

Perusahaan pesaing

Total pendapatan perusahaan Immutep Corp IMMP|Pendapatan perusahaan Anixa Biosciences, Inc. (ANIX)|atossatherapeutics.com - Volume dodolan perusahaan|Pendapatan perusahaan Context Therapeutics Inc. CNTX|MRSN - Dodolan perusahaan|BriaCell Therapeutics Corp - Pendapatan lan volume dodolan|Total pendapatan perusahaan ESSA Pharma Inc.|QT Imaging Holdings, Inc. (QTI) - Pendapatan perusahaan